SCHEMBL6490602

SCHEMBL6490602

Cc1cc(CO)cc2c1nc(C)n2Cc1ccc(Cl)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 1/20 0.41
VDR P11473 1/20 0.40
KMT2A Q03164 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
DCTPP1 Q9H773 7/20 0.39
NPSR1 Q6W5P4 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HPGD P15428 1/20 0.39
ALOX5AP P20292 1/20 0.38
GALR3 O60755 1/20 0.38
NR2F2 P24468 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492577 0.85 DCTPP1 (0.41) DCTPP1L3MBTL1ALOX5APGALR3NR2F2
SCHEMBL6489201 0.85 DCTPP1 (0.40) LMNASMN1; SMN2DCTPP1L3MBTL1HPGD
SCHEMBL6490954 0.83 TSHR (0.42) PPARGLMNATSHRVDRKMT2A
SCHEMBL6172911 0.81 PPARG (0.48) PPARGLMNATSHRVDRSMN1; SMN2
SCHEMBL6491398 0.80 VDR (0.49) PPARGLMNATSHRVDRKMT2A
SCHEMBL6171804 0.79 DCTPP1 (0.49) PPARGLMNATSHRVDRKMT2A
SCHEMBL6488419 0.78 LMNA (0.49) PPARGLMNATSHRSMN1; SMN2DCTPP1
SCHEMBL6498703 0.78 LMNA (0.39) PPARGLMNATSHRVDRKMT2A
SCHEMBL6491218 0.78 CD38 (0.44) PPARGLMNATSHRSMN1; SMN2DCTPP1
SCHEMBL6491685 0.78 FABP3 (0.46) LMNASMN1; SMN2ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD PPARG 233/4885LMNA 3711/4885TSHR 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.